Patrys Ltd., of Melbourne, Australia, reported preclinical data showing that its PAT-DX1, a humanized version of Deoxymab 3E10, acts synergistically with PARP inhibitor Lynparza (olaparib, Astrazeneca plc). Combinations of PAT-DX1 and olaparib were tested on both brain and colon cancer cells with defective DNA repair pathways.  Read More

SAN ANTONIO – Since overexpression of the HER2/Erbb2 receptor was first described as a feature of some breast cancer in 1987, the overexpression has been turned from a negative to a positive predictive factor by the efforts of first academic researchers and then the biopharmaceutical industry. Read More

Australia's CSL Ltd. said it expects to spend between $450 million and $550 million on its largest-ever study, a phase III trial of CSL-112, an I.V. infusion formulation of human apolipoprotein A-I intended to reduce early recurrent cardiovascular events in heart attack survivors. Separately, the company paid $15 million up front to spark a collaboration and purchase option agreement with Canada's Vitaeris Inc. Together, the companies will work to expedite the development of clazakizumab, an anti-IL-6 monoclonal antibody, as a therapy for solid organ transplant rejection. Read More

PERTH, Australia – IP Australia released its final recommendations on five separate intellectual property policy amendments put forward by the Productivity Commission that are expected to make their way through Parliament in 2018. Read More

HONG KONG – Controversy has continued to mount in the Philippines around Sanofi Pasteur Ltd.'s dengue vaccine, Dengvaxia, which is now facing questions about its effectiveness and the manner and speed with which the government adopted it in its national vaccination program. Read More